ストックスクリーナーアプリを入手
57.91
0.02%
-0.01
アフターアワーズ：
57.73
-0.18
-0.31%
前日終値:
$57.92
開ける：
$58.37
24時間の取引高:
145.30K
Relative Volume:
0.62
時価総額：
$387.54M
収益：
-
当期純損益:
$-13.72M
株価収益率:
-29.16
EPS:
-1.9861
ネットキャッシュフロー:
$-12.20M
1週間 パフォーマンス:
-0.21%
1か月 パフォーマンス:
-4.06%
6か月 パフォーマンス:
-35.95%
1年 パフォーマンス:
+50.96%
1日の値動き範囲:
$56.61
$59.72
1週間の範囲:
$54.67
$60.08
52週間の値動き範囲:
$28.40
$105.00
Monopar Therapeutics Inc Stock (MNPR) Company Profile
名前
Monopar Therapeutics Inc
セクター
電話
(847) 388-0349
住所
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
57.91 | 387.61M | 0 | -13.72M | -12.20M | -1.9861 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-09 | 開始されました | Morgan Stanley | Overweight |
| 2025-11-14 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2025-11-10 | 開始されました | Leerink Partners | Outperform |
| 2025-10-13 | 開始されました | Barclays | Overweight |
| 2025-09-09 | 開始されました | BTIG Research | Buy |
| 2025-09-03 | 開始されました | Oppenheimer | Outperform |
| 2025-09-03 | 開始されました | Raymond James | Strong Buy |
| 2025-08-26 | 再開されました | H.C. Wainwright | Buy |
| 2025-07-07 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-06-23 | 開始されました | Chardan Capital Markets | Buy |
| 2025-03-19 | 再開されました | Piper Sandler | Overweight |
| 2025-01-10 | 開始されました | Piper Sandler | Overweight |
| 2024-10-11 | 開始されました | Rodman & Renshaw | Buy |
| 2021-01-28 | 開始されました | ROTH Capital | Buy |
すべてを表示
Monopar Therapeutics Inc (MNPR) 最新ニュース
How (MNPR) Movements Inform Risk Allocation Models - Stock Traders Daily
Chardan Capital Reaffirms Buy Rating on MNPR with $100 Price Tar - GuruFocus
Is Monopar Therapeutics Inc a momentum stock2026 Earnings Surprises & Weekly Top Gainers Trade List - baoquankhu1.vn
Is Monopar Therapeutics Inc stock technically oversold2026 Risk Factors & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Q1 EPS Estimate for Monopar Therapeutics Boosted by Analyst - defenseworld.net
Monopar Therapeutics Inc (MNPR) Gets a Buy from JonesTrading - The Globe and Mail
Monopar Therapeutics Shows Rising Relative Strength; Still Shy Of Key Threshold - Investor's Business Daily
Gains Report: Will Monopar Therapeutics Inc benefit from sector rotationQuarterly Trade Review & Long Hold Capital Preservation Plans - baoquankhu1.vn
Trading Systems Reacting to (MNPR) Volatility - Stock Traders Daily
MNPR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Monopar Therapeutics Inc. (1IY0.SG) stock price, news, quote and history - Yahoo Finance Singapore
Monopar Therapeutics Inc. (1IY0.SG) Stock Price, News, Quote & History - Yahoo! Finance Canada
[Form 4] Monopar Therapeutics Insider Trading Activity - Stock Titan
Monopar Therapeutics (MNPR) COO gains shares through RSU vesting and tax withholding - Stock Titan
Monopar Therapeutics Inc. 2025 Annual Report Amendment: Financial Highlights, Corrections, and Key SEC Filings - Minichart
Monopar Therapeutics | 10-K/A: Annual report (Amendment) - Moomoo
Monopar (NASDAQ: MNPR) 10-K/A shows $13.7M loss but strong cash - Stock Titan
HC Wainwright Brokers Reduce Earnings Estimates for MNPR - MarketBeat
Monopar Therapeutics Inc. (1IY0.SG) Analyst Ratings, Estimates & Forecasts - Yahoo! Finance Canada
Monopar Therapeutics Inc (MNPR) Receives a Buy from Lake Street - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
MNPR SEC FilingsMonopar Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
MNPR's Rating Maintains 'Buy' by Chardan Capital: March 30, 2026 - GuruFocus
Chardan Capital Reaffirms "Buy" Rating for Monopar Therapeutics (NASDAQ:MNPR) - MarketBeat
Monopar Therapeutics stock price target maintained at $104 by BTIG - Investing.com Canada
Monopar Therapeutics Inc. Q4 and Full Year 2025 Earnings: Net Loss Narrows to $13.7M - Bayelsa Watch
Monopar Therapeutics (STU:1IY0) NonCurrent Deferred Revenue : €0.00 Mil (As of Sep. 2025) - gurufocus.com
Leerink reiterates Monopar stock rating on Wilson disease drug potential By Investing.com - Investing.com Canada
Raymond James reiterates Monopar stock rating on NDA timing shift By Investing.com - Investing.com Canada
Is Flanigans Enterprises Inc stock a hidden gem2026 Big Picture & Detailed Earnings Play Strategies - baoquankhu1.vn
Monopar Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
MNPR: ALXN1840 advances toward NDA in 2026 as financials improve and cash reserves strengthen - TradingView
Monopar (NASDAQ: MNPR) details 2025 loss and ALXN1840 NDA plan - Stock Titan
Monopar Therapeutics (NASDAQ:MNPR) Releases Quarterly Earnings Results, Misses Estimates By $0.10 EPS - MarketBeat
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update - The Manila Times
Monopar Therapeutics Q4 net loss narrows on lower R&D costs - TradingView
Monopar (NASDAQ: MNPR) 10-K outlines ALXN1840 deal, pipeline and runway - Stock Titan
Monopar Therapeutics Inc. Reports Q4 and Full-Year 2025 Financial Results and Highlights Progress for ALXN1840 in Wilson Disease - Quiver Quantitative
Monopar Therapeutics 10‑K: Net loss $13.7M, EPS $(1.85) with operating loss $(16.7M) - TradingView
MNPR: Year-end cash of $140.4M supports ongoing ALXN1840 and MNPR-101 trials; net loss was $13.7M - TradingView — Track All Markets
Wilson disease drug heads for mid-2026 filing as Monopar cash lasts to 2027 - Stock Titan
Raymond James Boosts Monopar Therapeutics (MNPR) PT to $142, Maintains Strong Buy - MSN
Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
How Monopar Therapeutics Inc. (MNPR) Affects Rotational Strategy Timing - Stock Traders Daily
Monopar Therapeutics (MNPR) to Release Earnings on Monday - MarketBeat
US Stocks Recap: Why is Monopar Therapeutics Inc stock going downProduct Launch & Safe Swing Trade Setups - baoquankhu1.vn
BTIG Initiates Coverage of Monopar Therapeutics (MNPR) with Buy Recommendation - MSN
Monopar Therapeutics Aktie: Positive Phase 1b Data for ALXN-802 Sparks Biotech Rally on Nasdaq - AD HOC NEWS
Jones Trading Downgrades Monopar Therapeutics (MNPR) - MSN
Monopar Therapeutics Inc. $MNPR Shares Acquired by Ally Bridge Group NY LLC - MarketBeat
(MNPR) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Monopar Therapeutics Inc (MNPR) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):